ANI Pharmaceuticals, Inc. (ANIP) fair value analysis

Nasdaq · Updated 2026-09-07

ANI Pharmaceuticals, Inc. is a pharmaceutical company that develops, manufactures, and distributes generic and branded medications. The company operates primarily in the United States, focusing on products across various therapeutic areas including pain management, cardiovascular health, and other specialty pharmaceuticals.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, ANIP is trading at more than a 25% discount to estimated fair value.

ANIP currently ranks #12 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $80.06
Sector: Healthcare
12-month range: $75.22–$94.06

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C-
Leverage: Moderate
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The lower-middle quarter of its range

What our data shows for ANIP

Our model validated 17 trailing price-to-earnings windows for ANIP, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $75.22–$94.06.
The 14-day relative strength index sits at a neutral 34.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for ANIP
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent ANIP news

TickrTrends' derived news-sentiment signal for ANIP is currently leaning positive, computed from recent coverage.

ANI Pharmaceuticals to Present at September Investor Conferences (manilatimes.net, 2026-09-03)
TickrTrends take: ANI Pharmaceuticals operates in the Healthcare sector where investor conferences provide opportunities for management to discuss operational progress and market positioning that can influence valuation assessments. TickrTrends currently derives an Undervalued verdict for ANIP, suggesting the market may not be fully pricing in developments that could be discussed at these September events. Valuation-focused readers should monitor whether conference presentations contain updates on product pipeline, revenue drivers, or strategic initiatives that could justify current pricing relative to fundamentals.
ANI Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ANIP) 2026-08-08 (seekingalpha.com, 2026-08-08)
TickrTrends take: ANI Pharmaceuticals released its 2026 second quarter earnings presentation, providing updated financial and operational metrics for investors to assess against current market pricing. Given TickrTrends' current undervalued designation for the stock, readers focused on valuation should examine whether the company's revenue trends, margin performance, and cash generation in the quarter support or challenge the assessment of ANIP relative to comparable Healthcare sector companies. The earnings data would be particularly relevant for determining if the company's trajectory justifies a revaluation or if the undervalued status reflects genuine fundamental strength.
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript (seekingalpha.com, 2026-08-07)
TickrTrends take: ANI Pharmaceuticals reported Q2 2026 results, providing updated financial performance data relevant to assessing whether its current undervalued classification remains justified. Valuation-focused readers should monitor whether the company's revenue trends, margin performance, and cash generation in the quarter support the thesis that ANIP's Healthcare sector positioning offers value at present levels. The earnings call details on product mix, competitive dynamics, and management guidance will be critical indicators of whether the undervaluation assessment reflects genuine upside potential or requires recalibration.

What people are saying

Follow the ANIP conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — ANIP's momentum indicator, which had registered a B grade last week, has declined to none this week. The stock maintains an undervalued valuation verdict in the Healthcare sector according to TickrTrends' derived indicators.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is ANIP stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), ANIP is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is ANIP's TickrTrends verdict?

ANIP's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does ANIP compare to other Healthcare stocks?

ANIP ranks #12 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is ANIP overbought or oversold?

ANIP's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

ANIP vs ALGN · ANIP vs AMPH · ANIP vs ASTH · ANIP vs BSX · ANIP vs COO